PARP1 and ovarian carcinoma: Cells with homozygous BRCA mutation are significantly more sensitive to platinum agents and PARP inhibitors than cells with heterozygous mutations in vitro and in murine models of pancreatic, breast, and ovarian cancers [13,14,98,99,100].